Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Adult Primary Myelodysplastic Syndrome: Experience from a Tertiary Care Center in Pakistan

  • Published : 2016.04.11
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Primary myelodysplastic syndrome (MDS) is an acquired clonal disorder of myeloid progenitor cells, characterized by peripheral cytopenias in the presence of hypercellular marrow with dysplastic features. Our aim was to study the demographical and clinicopathological features of adult Pakistani patients with MDS at disease presentation. Materials and Methods: This single centre study was conducted at Liaquat National Hospital and Medical College, extending from January 2010 to December 2014. Data were retrieved from the patient archives. Results: Overall 45 patients were diagnosed at our institution with de novo MDS during the study period. There were 28 males and 17 females. Age ranged between 18 and 95 years with a mean age of $57.6{\pm}17.4years$ and median of 64 years. The male to female ratio was 1.7:1. The main presenting complaints were generalized fatigue (60%), fever (33.3%), dyspnea (15.5%), bleeding (13.3%) and weight loss (11.1%). Examination was unremarkable in 42.2% of patients. Physical examination revealed pallor in 37.7%, followed by petechial and purpuric rashes in 20%. The commonest laboratory finding was anemia (hemoglobin < 10 g/dl in 41 (91.1%) patients. Out of these, 27 (60%) patients had normocytic anemia, followed by macrocytic (22.2%) and microcytic (8.8%). Conclusions: Primary MDS in Pakistani patients demonstrates a male preponderance. The proportion of anemic patients was high in our series with predominance of normocytic anemia. However, other clinico-hematological features appear comparable to published data.

Keywords

References

  1. Akinci S, Silay K, Ulas A, et al (2014). Neutrophil to lymphocyte ratio--not an independent prognostic factor in patients with the myelodysplastic syndrome. Asian Pac J Cancer Prev, 15, 10883-5.
  2. Bernasconi P, Klersy C, Boni M, et al (2005). Incidence and prognostic significance of karyotype abnormalities in de novo primary myelodysplastic syndromes: a study on 331 patients from a single institution. Leukemia, 19, 1424-31. https://doi.org/10.1038/sj.leu.2403806
  3. Brunning RD, Orazi A, Germing U, Le Beau MM. Myelodysplastic syndromes/neoplasms, overview. In: Swerdlow HS, Campo E, Haris LN, et al (2008). WHO classification of tumours of haemopoietic and lymphoid tissues. Lyon: International agency for research on cancer, 89.
  4. Chevassut TJ, Mufti GJ (2011). The myelodysplastic syndromes. In:Hoffbrand AV, Catovsky D, Tuddenham EG, Green AR. Post graduate hematology, 6th edition, 503.
  5. de Hollanda A, Beucher A, Henrion D, et al (2011). Systemic and immune manifestations in myelodysplasia: a multicenter retrospective study. Arthritis Care Res (Hoboken), 63, 1188-94. https://doi.org/10.1002/acr.20504
  6. Ehsan A, Aziz M (2010). Clinico-haematological characteristics in Pakistani patients of primary myelodysplastic syndrome according to World Health Organization classification. J Coll Physicians Surg Pak, 20, 232-6.
  7. Fenaux P, Haase D, Sanz GF, et al (2014). ESMO guidelines working group. Myelodysplastic syndromes: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol, 25, 57-69. https://doi.org/10.1093/annonc/mdt422
  8. Gao S, Li Z, Fu JH, et al (2015). Decitabine in the treatment of acute myeloid leukemia and myelodysplastic syndromes, which combined with complex karyotype respectively. Asian Pac J Cancer Prev, 16, 6627-32. https://doi.org/10.7314/APJCP.2015.16.15.6627
  9. Irfan M, Kakepoto GN, Khursheed M (1998).Primary myelodysplastic syndrome: clinical spectrum of 53 cases. J Pak Med Assoc, 48, 69-73.
  10. Iglesias Gallego M, Sastre Moral JL, Gayoso Diz P, et al (2003). Incidence andcharacteristics of myelodysplastic syndromes in Ourense (Spain) between 1994-1998. Haematologica, 88, 1197-9.
  11. Lau LG, Chng WJ, Liu TC, et al (2004). Clinico-pathological analysis of myelodysplastic syndrome according to French-American-British classification and international prognostic scoring system. Ann Acad Med (Singapore), 33, 589-95.
  12. Malcovati L, Hellstrom-Lindberg E, Bowen D, et al (2013). Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood, 122, 2943-64. https://doi.org/10.1182/blood-2013-03-492884
  13. Newman K, Maness-Harris L, El-Hemaidi I, Akhtari M (2012). Revisiting use of growth factors in myelodysplastic syndromes. Asian Pac J Cancer Prev, 13, 1081-91. https://doi.org/10.7314/APJCP.2012.13.4.1081
  14. Neukirchen J, Schoonen WM, Strupp C, et al (2011). Incidence and prevalence of myelodysplastic syndromes: data from the Dusseldorf MDS-registry. Leuk Res, 35, 1591-6. https://doi.org/10.1016/j.leukres.2011.06.001
  15. Rodrigues EF, de Souza DC, Camargo A, et al (2007). Cytogenetic biclonality in a child with hypocellular primary myelodysplastic syndrome. Cancer Genet Cytogenet, 178, 70-2. https://doi.org/10.1016/j.cancergencyto.2007.05.025
  16. Rashid A, Khurshid M, Shaikh U, Adil S (2014). Chromosomal abnormalities in primary myelodysplastic syndrome. J Coll Physicians Surg Pak, 24, 632-5.
  17. Shah NM, Prajapati SG, Adesara RP, Patel AP (2009). An analysis of 30 cases of myelodysplastic syndrome. Indian J Pathol Microbiol, 52, 206-9. https://doi.org/10.4103/0377-4929.48919
  18. Schnatter AR, Glass DC, Tang G, Irons RD, Rushton L (2008). Myelodysplastic syndrome and benzene exposure among petroleum workers: an international pooled analysis. J Natl Cancer Inst, 104, 1724-37.
  19. Wang XQ (2008). Sino-US shanghai leukemia cooperative group.who classification and cytogenetic analysis of 435 cases with myelodysplastic syndrome. Zhonghua Nei Ke Za Zhi, 47, 464-7.